Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis.
Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, Haack KA, Bolzani A, Siliman G, Hamed A.
J Neurol. 2019 Sep;266(9):2312-2321. doi: 10.1007/s00415-019-09401-1. Epub 2019 Jun 11.
Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.
Nathan SD, Wanger J, Zibrak JD, Wencel ML, Burg C, Stauffer JL.
Expert Rev Respir Med. 2021 Feb;15(2):175-181. doi: 10.1080/17476348.2020.1816831. Epub 2020 Sep 28.
[Spirometry: basic concepts].
Rivero-Yeverino D.
Rev Alerg Mex. 2019 Jan-Mar;66(1):76-84. doi: 10.29262/ram.v66i1.536.
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.
Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.
Adv Ther. 2019 Nov;36(11):3059-3070. doi: 10.1007/s12325-019-01093-3. Epub 2019 Sep 29.
Reduced Forced Vital Capacity Among Human Immunodeficiency Virus-Infected Middle-Aged Individuals.
Verboeket SO, Wit FW, Kirk GD, Drummond MB, van Steenwijk RP, van Zoest RA, Nellen JF, Schim van der Loeff MF, Reiss P; AGEhIV Study Group.
J Infect Dis. 2019 Apr 8;219(8):1274-1284. doi: 10.1093/infdis/jiy653.
Forced Vital Capacity and Low Frequency Reactance Area Measurements Are Associated with Asthma Control and Exacerbations.
Chan R, Lipworth B.
Lung. 2022 Jun;200(3):301-303. doi: 10.1007/s00408-022-00542-1. Epub 2022 Jun 3.
Changes in forced vital capacity over 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.
Berger KI, Chien YH, Dubrovsky A, Kishnani PS, Llerena JC Jr, Neilan E, Roberts M, Sheng B, Batista JL, Periquet M, Wilson KM, van der Ploeg AT.
J Neurol. 2024 Aug;271(8):5433-5446. doi: 10.1007/s00415-024-12489-9. Epub 2024 Jun 19.
Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease.
Distler O, Vonk MC, Azuma A, Mayes MD, Khanna D, Highland KB, Toenges G, Alves M, Allanore Y.
Arthritis Res Ther. 2025 Mar 21;27(1):63. doi: 10.1186/s13075-025-03524-9.
Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear.
Wells AU.
Thorax. 2013 Apr;68(4):309-10. doi: 10.1136/thoraxjnl-2012-202640. Epub 2012 Sep 27.
Assessing the quality of forced vital capacity measurement in patients with systemic sclerosis.
Uzun GS, Sarı A, Karcıoğlu O, Sancar EN, Unaldı E, Fırlatan B, Bayram GS, Kılıç L, Akdoğan A.
Semin Arthritis Rheum. 2024 Aug;67:152466. doi: 10.1016/j.semarthrit.2024.152466. Epub 2024 May 20.
